慢性淋巴细胞白血病预后研究进展：第57届美国血液学会年会报道

Research progress of the prognosis of chronic lymphocytic leukemia：reports from the 57th American Society of Hematology annual meeting

慢性淋巴细胞白血病（CLL）是一种恶性B细胞淋巴增殖性疾病，患者临床预后具有显著的异质性。近年来，随着免疫学、细胞遗传学及分子生物学的进展，出现了许多基于CLL遗传学、免疫表型、分子生物学特征的预后标志物。文章就第57届美国血液学会（ASH）年会上有关CLL预后的研究进展作一总结。

Chronic lymphocytic leukemia （CLL） is a kind of malignant B-cell chronic lymphoproliferative disorder with highly heterogeneous clinical courses. Due to the recent advances in immunology, cellular genetics and molecular biology, several prognostic markers based on genetic, phenotypic, and molecular biology characteristics of CLL cells have emerged in the past decade. This article reviews the reports from the 57th American Society of Hematology （ASH） annual meeting on the progress of the prognosis of CLL.